Claudio Papi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudio Papi has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Annalisa Aratari
7 shared publicationsAmbrogio Orlando
6 shared publications- Anna Kohn
Department of Gastroenterology, San Camillo-Forlanini Hospital, Rome, Italy
6 shared publications Livia Biancone
6 shared publications- Marco Daperno
Gastroenterology Unit, Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy
6 shared publications - Sara Onali
Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, 00133 Rome, Italy
6 shared publications
Latest Publications
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- 1 August 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (8) , 852-858
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy
Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall colectomy-free survival and the identification of predictors of colectomy. The 3- and 12-month colectomy rates were 18.6% (95%CI 11.8%-26.9%) and 25.6% (95%CI 17.9%-34.7%) respectively. High CRP values and severe endoscopic lesions were associated with the risk of colectomy: Risk Ratio (RR)=2.15 (95%CI 1.05-4.36), and RR=5.13 (95%CI 1.55-16.96), respectively. In patients escaping early colectomy, the probability of a colectomy-free course at 12, 24, 36 and 60months was 91%, 85%, 81% and 73%, respectively. Endoscopic severity was the only predictor of long term colectomy (RR=7.0; 95%CI 1.09-44.7). Adverse events occurred in 16 patients (14%); there was one death (0.88%) due to pulmonary abscess. Infliximab is an effective and safe rescue therapy for severe corticosteroid-refractory ulcerative colitis. A three-dose induction regimen seems to be the treatment of choice for preventing early colectomy. Severe endoscopic lesions appear to be predictor of short- and long-term colectomy.
- Open Access
- 1 December 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (12) , 978-985
Mucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors
- 1 December 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (12) , 978-985
Open AccessMucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Tu1144 Could Infliximab Avoid Colectomy in Patients With Severe Ulcerative Colitis? A Multicentre Italian Experience
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1917 Interobserver Agreement in IBD Endoscopic Scoring: Preliminary Results of an Ongoing IG-IBD Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1917 Interobserver Agreement in IBD Endoscopic Scoring: Preliminary Results of an Ongoing IG-IBD Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1887 Adalimumab in Active Ulcerative Colitis: A “Real-Life” Observational Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1887 Adalimumab in Active Ulcerative Colitis: A “Real-Life” Observational Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1270 Early Post-Operative Endoscopic Recurrence in Crohn's Disease Patients: Data From a Large Prospective Italian Multicenter Cohort
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1270 Early Post-Operative Endoscopic Recurrence in Crohn's Disease Patients: Data From a Large Prospective Italian Multicenter Cohort
- 1 March 2012
- Vol. 21 (1) , 67-73
Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
Current guidelines on the medical therapy of Crohn's disease recommend a step-up strategy consisting of a progressive intensification of treatment as the disease severity increases. In the last fifteen years, the introduction of biologic therapies, particularly anti-TNFα antibodies, has offered new therapeutic opportunities. The efficacy of anti-TNF-alpha therapy for inducing and maintaining clinical response or remission in moderate to severe Crohn's disease has been extensively evaluated in randomised controlled trials and meta-analyses. Moreover, anti-TNF-alpha therapy can induce mucosal healing and this property may be potentially disease-modifying. Consequently, an early introduction of biologics and/or immunomodulators (top-down strategy) in newly diagnosed Crohn's disease has been advocated. This paper will review the evidence in favour and against this approach to Crohn's disease therapy, discuss which patients are potential candidates to early aggressive treatment, and how a conventional step-up approach can be optimized. The conclusion is that an indiscriminate top-down approach does not seem to be appropriate for all patients with moderate to severe Crohn's disease.
- 1 March 2012
- Vol. 21 (1) , 67-73
Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
Current guidelines on the medical therapy of Crohn's disease recommend a step-up strategy consisting of a progressive intensification of treatment as the disease severity increases. In the last fifteen years, the introduction of biologic therapies, particularly anti-TNFα antibodies, has offered new therapeutic opportunities. The efficacy of anti-TNF-alpha therapy for inducing and maintaining clinical response or remission in moderate to severe Crohn's disease has been extensively evaluated in randomised controlled trials and meta-analyses. Moreover, anti-TNF-alpha therapy can induce mucosal healing and this property may be potentially disease-modifying. Consequently, an early introduction of biologics and/or immunomodulators (top-down strategy) in newly diagnosed Crohn's disease has been advocated. This paper will review the evidence in favour and against this approach to Crohn's disease therapy, discuss which patients are potential candidates to early aggressive treatment, and how a conventional step-up approach can be optimized. The conclusion is that an indiscriminate top-down approach does not seem to be appropriate for all patients with moderate to severe Crohn's disease.
- 30 September 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (9) , e18
Do not disturb the sleeping worm
- 30 September 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (9) , e18
Do not disturb the sleeping worm
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1257 Rifaximin® Reduces Symptoms and Complications in Patients With Symptomatic Diverticular Disease (SDD): A Meta-Analysis
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1257 Rifaximin® Reduces Symptoms and Complications in Patients With Symptomatic Diverticular Disease (SDD): A Meta-Analysis
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
S1214 Early Post-Operative Endoscopic Recurrence in Crohn's Disease in an Italian Multicentric Cohort
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
S1214 Early Post-Operative Endoscopic Recurrence in Crohn's Disease in an Italian Multicentric Cohort